Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
338 studies found for:    "Anaplastic large cell lymphoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Anaplastic large cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-Cell Lymphoma
Intervention: Drug: SGN-30 (anti-CD30 mAb)
2 Terminated
Has Results
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: SGN-30
3 Recruiting A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
Condition: Systemic Anaplastic Large-Cell Lymphoma
Intervention: Drug: crizotinib
4 Recruiting Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
5 Terminated
Has Results
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma
Interventions: Biological: monoclonal antibody SGN-30;   Drug: therapeutic hydrocortisone;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide;   Drug: methotrexate;   Drug: cytarabine;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Not yet recruiting Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   Systemic Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Ceritinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Intervention: Drug: Brentuximab vedotin (recombinant)
8 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine;   Drug: Neulasta
9 Completed Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Intervention: Biological: XmAb2513
10 Active, not recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
11 Completed
Has Results
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Brentuximab vedotin and rifampicin
12 Withdrawn Denileukine Diftitox for Relapsed ALCL
Condition: Anaplastic Large-Cell Lymphoma
Interventions: Drug: Denileukin Diftitox;   Drug: Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide
13 Completed
Has Results
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: tanespimycin
14 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
15 Recruiting Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Conditions: Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: questionnaire administration
16 Recruiting Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive;   CD30-Positive Neoplastic Cells Present;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate
17 Completed Biomarker Expression in Samples From Young Patients With Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: western blotting;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry
18 Completed
Has Results
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: vinblastine sulfate;   Drug: vincristine sulfate
19 Active, not recruiting Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: carmustine;   Drug: cyclosporine;   Drug: cytarabine;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: idarubicin;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: lomustine;   Drug: melphalan;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: prednisolone;   Drug: thiotepa;   Drug: vinblastine sulfate;   Drug: vindesine;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
20 Unknown  Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: vinblastine sulfate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.